PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?

SIMPLE SUMMARY: Melanomas with homologous recombination DNA damage repair pathways represent a subset of melanoma that may benefit from PARP inhibitors and immunotherapy. PARP inhibitors have an established role in treating cancers with underlying BRCA mutation through synthetic lethality; however,...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Wei Yen, Brown, Lauren J., Reid, Lee, Joshua, Anthony M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464708/
https://www.ncbi.nlm.nih.gov/pubmed/34572747
http://dx.doi.org/10.3390/cancers13184520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464708/
https://www.ncbi.nlm.nih.gov/pubmed/34572747
http://dx.doi.org/10.3390/cancers13184520

Ejemplares similares